company background image
VRCA logo

Verrica Pharmaceuticals NasdaqGM:VRCA Stock Report

Last Price

US$0.69

Market Cap

US$61.2m

7D

-8.8%

1Y

-89.8%

Updated

20 Dec, 2024

Data

Company Financials +

Verrica Pharmaceuticals Inc.

NasdaqGM:VRCA Stock Report

Market Cap: US$61.2m

My Notes

Capture your thoughts, links and company narrative

Verrica Pharmaceuticals Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Verrica Pharmaceuticals
Historical stock prices
Current Share PriceUS$0.69
52 Week HighUS$11.41
52 Week LowUS$0.61
Beta1.4
1 Month Change-21.77%
3 Month Change-61.65%
1 Year Change-89.82%
3 Year Change-92.64%
5 Year Change-95.63%
Change since IPO-96.03%

Recent News & Updates

Recent updates

The Price Is Right For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Even After Diving 49%

Oct 03
The Price Is Right For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Even After Diving 49%

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Aug 17
Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Analysts Are Cutting Their Estimates: Here's What You Need To Know

With A 67% Price Drop For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) You'll Still Get What You Pay For

Aug 16
With A 67% Price Drop For Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) You'll Still Get What You Pay For

Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Jul 21
Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Jan 11
Is Verrica Pharmaceuticals (NASDAQ:VRCA) Using Debt In A Risky Way?

Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation

Jun 28
Here's Why We're Not At All Concerned With Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Situation

We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely

Feb 05
We're Hopeful That Verrica Pharmaceuticals (NASDAQ:VRCA) Will Use Its Cash Wisely

Vectoring Back In On Verrica Pharmaceuticals

Aug 31

Verrica Pharmaceuticals reports insider buying

Jul 06

Verrica Pharmaceuticals stock slides on proposed share offering

Jun 29

Verrica Pharmaceuticals Should Receive Second CRL Today

May 24

Shareholder Returns

VRCAUS PharmaceuticalsUS Market
7D-8.8%-2.0%-3.5%
1Y-89.8%7.6%22.1%

Return vs Industry: VRCA underperformed the US Pharmaceuticals industry which returned 7.6% over the past year.

Return vs Market: VRCA underperformed the US Market which returned 22.1% over the past year.

Price Volatility

Is VRCA's price volatile compared to industry and market?
VRCA volatility
VRCA Average Weekly Movement21.8%
Pharmaceuticals Industry Average Movement10.5%
Market Average Movement6.3%
10% most volatile stocks in US Market17.0%
10% least volatile stocks in US Market3.1%

Stable Share Price: VRCA's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: VRCA's weekly volatility has increased from 15% to 22% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013100Jayson Riegerwww.verrica.com

Verrica Pharmaceuticals Inc., a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts. The company also develops VP-315, an oncolytic peptide-based injectable therapy, which is in phase II clinical trial for the treatment of dermatology oncologic conditions which includes basal cell carcinoma; and VP-103, a cantharidin-based product candidate for the treatment of plantar warts and is in phase II clinical trial.

Verrica Pharmaceuticals Inc. Fundamentals Summary

How do Verrica Pharmaceuticals's earnings and revenue compare to its market cap?
VRCA fundamental statistics
Market capUS$61.25m
Earnings (TTM)-US$84.99m
Revenue (TTM)US$9.21m

6.8x

P/S Ratio

-0.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VRCA income statement (TTM)
RevenueUS$9.21m
Cost of RevenueUS$22.68m
Gross Profit-US$13.47m
Other ExpensesUS$71.52m
Earnings-US$84.99m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.94
Gross Margin-146.28%
Net Profit Margin-922.81%
Debt/Equity Ratio-127.2%

How did VRCA perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/20 00:59
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Verrica Pharmaceuticals Inc. is covered by 12 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jason Matthew GerberryBofA Global Research
Brian Kemp DolliverBrookline Capital Markets
Oren LivnatH.C. Wainwright & Co.